Swiss drug giant Roche reportedly readies to buy the biotech behind the first FDA-approved gene therapy and the priciest medicine in the US
Roche could pay $5 billion for biotech company Spark Therapeutics. The pharma giant likely wants to expand its presence in hemophilia, a lucrative market.
✍ Source Link : ☕ Business Insider Malaysia
Source :
(✿◠‿◠)✌ Enjoy reading and not forget to👍 Like & 💕 Share!
✍ Source Link : ☕ Business Insider Malaysia
Source :
(✿◠‿◠)✌ Enjoy reading and not forget to👍 Like & 💕 Share!
Post a Comment